Document:

Offer Letter

 Exhibit 10.15(A) 

 
 

 
 February 5, 2007 
 Dr. Steven Benner 
 [Address] 
 Dear Steven, 
 It gives me great pleasure to offer you the position of Senior Vice President and
Chief Medical Officer of OncoMed Pharmaceuticals, Inc. (“OncoMed” or “the Company”). 
 The terms of our
offer to you are as follows: 
  

			
	Title:	  	Senior Vice President and Chief Medical Officer
		
	Reporting to:	  	Paul J. Hastings, President & CEO
		
	Base Salary:	  	Your Base Salary will be $28,333.00 per month (a $340,000 annualized rate), payable in accordance with customary Company payroll procedures then in effect for others employed by
the Company, subject to review on an annual basis.
		
	Annual Bonus:	  	Bonus eligibility up to 25% of your base salary. This Bonus will be based upon achievement of (1) corporate goals and (2) specific department and personal goals to be agreed to
by the President & CEO.
		
	Stock Options	  	Subject to final approval of the Board, you will be granted an option to purchase 575,000 shares of common stock of Company (the “Option”). At your request, the Option
shall be an incentive stock option to the maximum extent permitted under the applicable federal income tax rules and shall have an exercise price equal to the fair market value of Company’s stock as of the date the Option is granted. Subject to
your remaining continuously employed by Company as of each

  
 - 1 -

			
		  	such date the Option shall vest and become exercisable with respect to 20% of the shares subject to the Option on the first anniversary of your commencement of employment, and
shall become vested in equal monthly installments thereafter, such that the Option is vested and exercisable with respect to 100% of the shares subject to the Option on the fifth anniversary of the Option’s date of grant. The specific terms of
the Option grant will be set forth in a written Stock Option Agreement between you and the Company which will be executed after your employment commences with Company. You will also be eligible for additional stock option grants, based on your
performance, and as part of general company practices.
		
	Change of Control	  	In the event of a “Change In Control” (as defined in the OncoMed Pharmaceuticals, Inc. Stock Incentive Plan), the vesting of an additional 12 months of any
then-unvested shares or stock options will be accelerated. The balance will continue to vest at the same monthly rate as they would have vested if no such acceleration had occurred. In addition, in the event that you are terminated without
“Cause” or terminate your own employment for “Good Reason” (as defined below) within eighteen months after a “Change in Control,” 50% of any shares or stock options which are not vested at the time of your termination
will accelerate and become vested. In the event of termination without “Cause” or for “Good Reason” your Base Salary will continue for six months and your basic employee benefits for twelve months. Payments will be made during
the continuation period according to the Company’s normal payroll policy. Receipt of the salary and benefits provided to you under this paragraph will be conditioned on your executing a standard form of release of the Company and associated
persons from any claims against the Company and such associated persons, and subject to mitigation obligations. In this context “Cause” shall mean (i) your gross negligence, willful misconduct, or repeated, willful and
flagrant

  
 2 

			
		  	insubordination in the performance of your duties to the Company as directed by the Board which remains uncured more than thirty days following written notice from the Board of
its belief that there is Cause for your termination under this clause (i); (ii) repeated unexplained or unjustified absence from the Company; (iii) a material and willful commission of any federal or state felony; (iv) commission of any act of fraud
with respect to the Company; or (v) conviction of a felony or a crime involving moral turpitude causing material harm to the standing and reputation of the Company , or any willful violation of a Federal or State law that significantly reduces the
credibility of the company, or affects the company in a materially financial way. No act or failure to act by you shall be deemed “willful” if done or omitted to be done by you in good faith and with the reasonable belief that your act or
omission was in the best interest of the Company or consistent with the Company’s policies or the directive of the Board. For purposes of this letter agreement, “Good Reason” shall mean your termination of your employment following a
Change in Control by reason of the material diminution of your duties and responsibilities (such as the loss of oversight as Chief Medical Officer or the senior officer responsible for clinical development, clinical operations, data management,
regulatory, and clinical safety of the Company’s operations such that your overall responsibilities are materially reduced), the reduction of your overall compensation other than as a part of a general reduction for all executive officers, or
the transfer of your principal place of business for the Company more than 10 miles south or west, or 50 miles north or east from the Company’s current Redwood City, California location.
		
	Vacation:	  	In accordance with Company policy.
		
	Benefit Plans:	  	You shall be entitled to the Company’s basic employment benefits available to all Company employees, as the same currently exists or may

  
 3 

			
		  	exist in the future. You acknowledge that participation in Company benefit programs may require payroll deductions and/or direct contributions by you.
		
	At Will:	  	The Company’s employees serve on an at-will basis. Your employment is voluntary and for no set period. If you accept employment with the Company, you will be free to resign
at any time. Likewise, the Company will be free to terminate your employment at any time, with or without good cause or for any or no cause.
		
	Employment Terms:	  	This offer of employment is contingent upon your signing and returning to the Company on or before your employment start date, the Company’s standard form of
“Confidential Information and Invention Assignment Agreement.” That agreement provides, among other things, that you will not solicit employees of the Company for a period of one year following termination of your employment by the Company
for any reason. In addition, you will not accept any additional outside business responsibilities (such as serving on the Board of Directors of other companies) without the prior approval of the President and CEO of OncoMed.
		
	Expenses:	  	The Company will reimburse reasonable business-related expenses incurred by you in accordance with applicable Company policies.
		
	Start Date:	  	As soon as practicable, at your election, but in no event later than February 16, 2007. Please be advised that your employment is contingent on your ability to prove your
authorization to work in the United States. You must comply with the Immigration and Naturalization Service’s employment verification requirements.

 Please note that this offer letter sets forth the entire agreement and understanding between you and the
Company regarding your employment relationship and supersedes any other written or oral representation, promise or discussion. 

  
 4 

 To indicate your acceptance of this offer, please sign and return one copy of this letter to
me. Steve, we are very much looking forward to having you as Senior Vice President and Chief Medical Officer. 
  

	
	 Yours very truly,

	
	 /s/ Paul J. Hastings

	 Paul Hastings

President and Chief Executive Officer

OncoMed Pharmaceuticals, Inc.

 By accepting this offer you agree this is a full-time position, and you will make every effort necessary to perform
adequately the duties that are assigned to you. 
 Agreed and accepted: 

 

							
	 /s/    Steven
Benner        
 Steven Benner
	 		 	 05 FEB 07

Date
	 	

  
 5Separation Agreement and General Release

 Exhibit 10.15(B) 

Confidential 
 SEPARATION AGREEMENT AND GENERAL RELEASE 
 This
Separation Agreement and General Release (the “Agreement”) is made effective as of the eighth
(8th) day following the date Executive signs this
Agreement (the “Effective Date”) by and between Steven E. Benner, M.D. (“Executive”) and OncoMed Pharmaceuticals, Inc. (the “Company”), with reference to the following facts: 

A. Executive’s employment with, and his position as Senior Vice President and Chief Medical Officer of, the Company will end
effective upon the Termination Date (as defined below). 
 B. Executive and the Company want to end their relationship amicably
and also to establish the obligations of the parties including, without limitation, all amounts due and owing to the Executive. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows: 

1. Employment Separation Date. Executive acknowledges that his status as an officer and employee of the Company terminated
effective November 18, 2011 (the “Termination Date”). 
 2. Severance Payments and Benefits.

 (a) Severance Payments. Contingent upon Executive’s execution of this Agreement without
revocation, during the period commencing on the later of (i) November 19, 2011 or (ii) the payroll date that is at five business days following the Effective Date and ending six months thereafter, the Executive shall continue to
receive his regular base salary, as in effect on November 18, 2011, less all applicable taxes and other authorized withholding and paid in accordance with the Company’s normal payroll practices (the “Severance Payments”).

 (b) Expense Reimbursements. The Company shall promptly reimburse Executive for all as yet unreimbursed
business expenses reimbursable under the Company’s expense reimbursement policy, providing Executive submits the expenses to the Company within fifteen (15) days after signature of this Agreement. 

  
 1 

 Confidential 
  

 (c) Healthcare Continuation. After November 30, 2011,
Executive and/or Executive’s covered dependents may elect to receive continued healthcare coverage, pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”). Contingent upon
Executive’s execution of this Agreement without revocation, and provided that Executive and/or his covered dependents elect to receive COBRA benefits, the Company shall reimburse Executive for the amount of COBRA premiums paid in excess of the
Executive’s normal contribution to medical, dental and vision benefits through the earlier of (i) May 31, 2012, or (ii) the date upon which Executive and/or his covered dependents are no longer eligible for COBRA. 

(d) Stock Options. The Company and Executive acknowledge and agree that, as of November 18, 2011, Executive
holds 267,783 options (collectively, the “Stock Options”) to purchase shares of Company common stock that are unvested, or as to which the Company has a right of repurchase, and 836,714 shares of Company common stock that are
vested, or as to which the Company’s right of repurchase has expired. All unvested Stock Options shall be cancelled as of the Termination Date. Except as so expressly stated, the Executive’s rights with respect to all Stock Options shall
be governed by the terms of the applicable Stock Option Plan(s), Agreement(s) and Notice(s) of Grant. 
 (e)
Taxes. Executive understands and agrees that all payments under Section 2 of this Agreement will be subject to any legally required tax withholdings. To the extent any personal income taxes may be payable by the Executive for the
benefits provided to him under Section 2 of this Agreement beyond those withheld by the Company, Executive agrees to pay them himself and to indemnify and hold the Company and the other entities released herein harmless for any tax claims or
penalties resulting from any failure by him to make required personal income tax payments. 
 (f) Sole
Separation Benefit. Executive agrees that this Agreement supersedes and replaces the severance terms of the employment offer letter between the Executive and the Company dated February 5, 2007 (the “Employment Agreement”)
and the Change in Control and Severance Agreement executed by the Executive effective July 30, 2009 (“Change in Control Agreement”), and that Company has no further obligations to the Executive under the terms of the Employment
Agreement or Change in Control Agreement. 
 3. Full Payment. Executive acknowledges that the payment and arrangements
herein shall constitute full and complete satisfaction of any and all amounts properly due and owing to Executive as a result of his employment with the Company and the termination thereof. 

  
 2 

 Confidential 
  

 4. Executive’s Release of the Company. Executive understands that by
agreeing to the release provided by this Section 4, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its employees or other agents for any reason whatsoever related to his employment or his ownership
of equity or options to purchase equity in the Company, based on anything that has occurred as of the date Executive signs this Agreement. 
 (a) On behalf of Executive and Executive’s heirs and assigns, Executive hereby releases and forever discharges the “Releasees” hereunder, consisting of the Company and Execustaff HR,
and each of their respective owners, affiliates, divisions, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and
from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or
unknown, fixed or contingent related to his employment or his ownership of equity or options to purchase equity in the Company (hereinafter called “Claims”), which Executive now has or may hereafter have against the Releasees, or
any of them, by reason of any matter, cause, or thing including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive’s hire, employment, remuneration or termination by the Releasees,
or any of them, including without limitation any and all Claims arising under federal, state, or local laws relating to employment, claims of any kind that may be brought in any court or administrative agency, any claims arising under the Age
Discrimination in Employment Act (“ADEA”), as amended, 29 U.S.C. § 621, et seq.; the Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq.; the Equal
Pay Act, as amended, 29 U.S.C. § 206(d); the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601 et seq.; the Americans with Disabilities Act of 1990, 42 U.S.C. §
12101 et seq.; the False Claims Act , 31 U.S.C. § 3729 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended,
29 U.S.C. § 2101 et seq. the Fair Labor Standards Act, 29 U.S.C. § 215 et seq., the Sarbanes-Oxley Act of 2002; the California Fair Employment and Housing Act; the California Family Rights Act; the California Labor Code;
California Business & Professions Code Section 17200 in connection with any Claims related to Executive’s employment or ownership of equity or options to purchase equity in the Company, ordinance or statute regarding employment;
Claims any other local, state or federal law governing employment; Claims for breach of contract entered into in conjunction with Executive’s employment or ownership of equity or options to purchase equity in the Company; Claims arising in tort
regarding Executive’s employment or ownership of equity or options to purchase equity in the Company, including, 

  
 3 

 Confidential 
  

 
without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of
public policy, and/or breach of the implied covenant of good faith and fair dealing, all in connection with Executive’s employment or ownership of equity or options to purchase equity in the Company; and Claims for damages or other remedies of
any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees, all in connection with Executive’s employment or ownership of equity or options to purchase equity in the Company.

 (b) Notwithstanding the generality of the foregoing, Executive does not release the following claims:

 (i) Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of
applicable state law; 
 (ii) Claims for workers’ compensation insurance benefits under the terms of any
worker’s compensation insurance policy or fund of the Company; 
 (iii) Claims to continued participation
in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA; 
 (iv)
Claims for indemnification under California Labor Code Section 2802; 
 (v) Executive’s right to bring
to the attention of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s right to secure any damages for alleged discriminatory treatment; 

(vi) All rights arising out of this Agreement; 

(vii) All rights Executive has or may have in the future, as a holder of shares in the Company; and 

(viii) Any other Claims that cannot be released as a matter of law. 

(c) In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:

  
 4 

 Confidential 
  

 (i) Executive has the right to consult with an attorney before signing
this Agreement; 
 (ii) Executive has been given at least twenty-one (21) days to consider this Agreement;

 (iii) Executive has seven (7) days after signing this Agreement to revoke it. If Executive wishes to
revoke this Agreement, Executive must deliver notice of Executive’s revocation in writing by facsimile or email, no later than 5:00 p.m. on the 7th day following Executive’s execution of this Agreement to Alicia J. Hager, Vice President,
Legal Affairs, OncoMed Pharmaceuticals, 80 Chesapeake Drive, Redwood City, CA 94063, fax: (650) 298-8600, email: Alicia.Hager@oncomed.com. 
 5. The Company’s Release of Executive. The Company, on behalf of itself, its insurers and successors in interest, and all persons claiming by, on behalf of, or through the Company,
agrees not to sue, or otherwise file any claim against the Executive, Executive’s heirs and assigns, successor in interests, agents and attorneys (the “Executive’s Releasees”), for any reason whatsoever based on anything
that has occurred as of the date Executive signs this Agreement. The Company, on behalf of itself and its affiliates, divisions, predecessors, successors, assigns, agents, and insurers, and all persons claiming by, on behalf of, or through the
Company, hereby releases and forever discharges Executive’s Releasees of and from any and all actions or claims, in law or in equity, of any nature whatsoever, known or unknown, related to Executive’s work and employment with the Company
(hereinafter called “Company’s Claims”), which the Company now has or may hereafter have against the Executive or Executive’s Releasees. Notwithstanding the generality of the foregoing, the Company does not release any
Company Claims, or the right of the Company to bring any action, legal or otherwise, against the Executive as a result of any failure by him to perform his obligations under this Agreement or the Confidentiality Agreement, or as a result of any acts
of intentional misconduct (including but not limited to fraud, embezzlement, misappropriation or other malfeasance). 
 6.
Waiver of Unknown Claims. EXECUTIVE AND THE COMPANY, AND EACH OF THEM, ACKNOWLEDGE THAT THEY HAVE BEEN ADVISED OF AND ARE FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS: 

“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR

  
 5 

 Confidential 
  

 
AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 

BEING AWARE OF SAID CODE SECTION, EXECUTIVE AND THE COMPANY, AND EACH OF THEM, HEREBY EXPRESSLY WAIVE ANY RIGHTS THEY MAY HAVE THEREUNDER, AS WELL AS
UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT, TO THE EXTENT OF THEIR RESPECTIVE RELEASES. 
 7.
Non-Disparagement, Transfer of Company Property, Response to Third Party Inquiries. The parties further agree that: 
 (a) Non-Disparagement. Executive agrees that he shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners,
shareholders or employees, either publicly or privately. The Company agrees that it shall not, and it shall instruct its officers and members of its Board of Directors to not disparage, criticize or defame Executive, either publicly or privately.
Nothing in this Section 6(a) shall have application to any evidence or testimony required by any court, arbitrator or government agency. 
 (b) Transfer of Company Property. Within five days of the Termination Date, Executive shall return his Company-issued laptop computer, with all Company files and data intact, and shall return all
files, memoranda, records, and other documents, and any other physical or personal property (including but not limited to Executive’s access card) which are the property of the Company and which he has in his possession, custody or control.
Executive may retain his Company-issued Blackberry, and the Company will cooperate with Executive in transferring to him the Blackberry number and service contract; provided, however, that Executive shall give the Blackberry to the Company’s IT
personnel within five days of the Termination Date so that the Company can remove from the Blackberry all Company information and files and shall return the Company-issued laptop with all Company data and files intact. 

(c) Response to Third Party Inquiries. The Company will respond as follows to inquiries from any third party about
Executive’s separation: “Following four years of heading OncoMed’s clinical programs, Dr. Benner has elected to move onto new professional challenges. Dr. Benner has provided critical leadership and guidance during a key
juncture in OncoMed’s development. OncoMed is grateful for his contributions and wishes him success in his future endeavors.” 
 8. Representations. 
 (a) Executive’s
Representations. Executive warrants and represents that (i) he has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that
if, unbeknownst to Executive such a complaint, charge or lawsuit has been filed on his behalf, he will immediately cause it to be withdrawn and dismissed, (ii) Executive has 

  
 6 

 Confidential 
  

 
reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which he may be entitled and no other compensation,
wages, bonuses, commissions and/or benefits are due to him, except as provided in this Agreement, (iii) Executive has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested
under the Family and Medical Leave Act or any similar state law, (iv) the execution, delivery and performance of this Agreement by the Executive does not and will not conflict with, breach, violate or cause a default under any agreement,
contract or instrument to which the Executive is a party or any judgment, order or decree to which the Executive is subject, and (v) upon the execution and delivery of this Agreement by the Company and the Executive, this Agreement will be a
valid and binding obligation of the Executive and Company, as applicable, enforceable in accordance with its terms. 
 (b) The Company’s Representations. Company warrants and represents that (i) it has not filed or authorized the filing of any complaints, charges or lawsuits against the Executive or any
of the Executive Releasees with any governmental agency or court, and that if, unbeknownst to Company such a complaint, charge or lawsuit has been filed on its behalf, it will immediately cause it to be withdrawn and dismissed, (ii) the
execution, delivery and performance of this Agreement by the Company does not and will not conflict with, breach, violate or cause a default under any agreement, to which the Company is a party or any judgment, order or decree to which the Company
is subject. 
 9. No Assignment. Executive warrants and represents that no portion of any of the matters released herein
has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or
instituted against the Company or any affiliate of the Company because of any actual assignment, subrogation or transfer by Executive, Executive shall indemnify and hold harmless the Company or any affiliate of the Company against such claim,
action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. The Company warrants and represents that no portion of any claims that it may have against the Executive have been assigned or transferred to any
other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Executive by any third
party because of any actual assignment, subrogation or transfer by the Company, the Company shall indemnify and hold harmless the Executive against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’
fees and costs. 

  
 7 

 Confidential 
  

 10. Governing Law. This Agreement shall be construed and enforced in accordance
with, and the rights of the parties shall be governed by, the laws of the State of California or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions of any state other than California.

 11. Miscellaneous. This Agreement, together with the Employee’s Proprietary Information and Inventions Agreement
and the agreements evidencing the Stock Options, constitutes the entire agreement between the parties with regard to the subject matter hereof and supersedes in its entirety the Change in Control Agreement, and the Employment Agreements between the
Company and Executive dated as of February 5, 2007 and between ExecustaffHR and Executive dated as of February 16, 2007. The Company and Executive acknowledge that the termination of the Executive’s employment with the Company is
intended to constitute an involuntary “separation from service” for the purposes of Section 409A of the Code, and the related Department of Treasury regulations. Executive and Company acknowledge that there are no other agreements,
written, oral or implied, and that they may not rely on any prior negotiations, discussions, representations or agreements. This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is
intended to modify this Agreement. This Agreement may be executed by facsimile transmission or by signing, scanning and emailing and in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one
and the same agreement. 
 12. Executive’s Cooperation. Executive shall cooperate with the Company and its
affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive’s duties and responsibilities to the Company
during his employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s reasonable request to give testimony
without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive’s possession during his employment); provided, however, that
any such request by the Company shall not be unduly burdensome or interfere with Executive’s personal schedule or ability to engage in gainful employment or consulting work.

(Signature page(s) follow) 

  
 8 

 Confidential 
  

 IN WITNESS WHEREOF, the undersigned have caused this Separation Agreement and General
Release to be duly executed and delivered as of the date indicated next to their respective signatures below. 
  

							
	DATED: 22 November, 2011	 		 		 	
			
		 		 	 /s/ Steven Benner

		 		 	Steven E. Benner, M.D.
			
		 		 	ONCOMED PHARMACEUTICALS
				
	DATED: November     , 2011	 		 		 	
				
		 		 	By:	 	  

		 		 		 	Paul Hastings
		 		 		 	President & Chief Executive Officer
			
	DATED: November 22,2011	 		 	On behalf of Paul J. Hastings:
			
		 		 	 /s/ William D. Waddill

		 		 	William D. Waddill
		 		 	Senior Vice President,
		 		 	Chief Financial Officer

  
 S-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]